NEW YORK (GenomeWeb) – SpeeDx said today that it has entered a test development collaboration with British drugmaker GlaxoSmithKline.
According to Sydney-based SpeeDx, it will provide GSK with a combination of existing and custom-developed molecular diagnostic tests to support its antibiotic clinical trials, as well as its new product development efforts.
Additional terms were not disclosed.
"We welcome this extension of the utility and application of our tests and technology," SpeeDx CEO Colin Denver said in a statement. "Our tests currently used in clinical practice are supporting resistance guided therapy, positively impacting cure rates and helping to minimize the spread of antimicrobial resistant infections."